Last updated: March 31, 2026
What is NDC 83324-0064?
NDC 83324-0064 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in May 2019 for spinal muscular atrophy (SMA) types 1, 2, and 3. It is a one-time intravenous infusion designed to address a genetic deficiency of survival motor neuron (SMN) protein.
Market Overview
Indication and Patient Population
- Primary indication: SMA type 1, 2, and 3, primarily affecting infants, children, and some adults.
- Market size estimate: In the U.S., approximately 1,200 infants and from 1,300 to 2,000 older patients diagnosed with SMA annually (SMA Foundation, 2021).
Competitive Landscape
- Main competitors: Spinraza (nusinersen, Biogen), Evrysdi (risdiplam, Roche).
- Market share (2022): Zolgensma captured around 30% of SMA-specific sales, owing to its single-dose administration and high price point.
- Approval timeline: Zolgensma received FDA approval in 2019; subsequent approvals in Europe, Japan, and other markets between 2020-2022.
Market Drivers
- Increased SMA diagnosis through newborn screening.
- Growing awareness and approvals for broader age groups.
- Expanding reimbursement policies in multiple jurisdictions.
Price Structure
- List price (U.S.): $2.125 million per dose (as of 2023).
- Price considerations: Based on a one-time infusion, distinct from ongoing treatments like Spinraza (~$750,000 over first year) and Evrysdi (~$34,000/month).
Revenue Estimates and Market Penetration
| Year |
Estimated Patients (U.S.) |
Expected Market Penetration |
Gross Revenue (USD millions) |
| 2022 |
450 |
25% |
956 |
| 2023 |
550 |
30% |
1,170 |
| 2024 |
650 |
35% |
1,472 |
| 2025 |
750 |
40% |
1,599 |
Note: The patient estimates reflect diagnosed cases and the degree of uptake influenced by approval expansions, payer access, and real-world diagnosis rates.
Price Projection Factors
Market Evolution
- Pricing pressures: Payers increasingly negotiate discounts and rebates.
- Reimbursement trends: Payor coverage for high-cost gene therapies varies; value-based agreements are emerging.
- Global pricing: Typically lower outside the U.S., with countries like the UK, Germany, and Japan setting prices 20-50% lower.
Policy Trends
- Cost-effectiveness evaluations: The Institute for Clinical and Economic Review (ICER) assesses value; some reports suggest prices above $1 million are above willingness-to-pay thresholds.
- Potential price adjustments: Future discounts and rebate schemes could lower effective prices by 10-30%.
Patent & Competition Impact
- Patent protections extend until at least 2030.
- Biosimilar or alternative gene therapies may enter the market post-2030, pressuring prices.
Future Price Forecast (2023-2025)
| Year |
Estimated Price (USD) |
Influence Factors |
| 2023 |
$2.125 million |
Stable pricing, high demand |
| 2024 |
$2.0 million* |
Reimbursement negotiations, potential discounts |
| 2025 |
$1.9 million* |
Increased competition, payor cost management strategies |
*Projected discounts from list price due to market dynamics.
Risks to Price Outlook
- Regulatory actions to enforce price controls.
- Changes in reimbursement policies favoring value-based pricing.
- Entry of competitors introducing alternative therapies or biosimilars.
- Adoption of expanded indications reducing per-patient cost recovery.
Key Takeaways
- NDC 83324-0064 (Zolgensma) commands a high list price (~$2.125M) driven by its one-time gene therapy model.
- Market penetration is expected to grow with increasing diagnosis rates and expanded age indications.
- Revenue projections suggest annual sales surpassing $1 billion by 2024 in the U.S.
- Price discounts of 10-30% are likely in subsequent years due to payer negotiations and competitive pressures.
- Long-term, patent protections and emerging biosimilars could influence pricing and market share.
FAQs
-
What are the primary competitors to Zolgensma?
Spinraza (nusinersen) and Evrysdi (risdiplam) are the main competitors, offering chronic, repeat dosing regimens.
-
How sustainable is the high price of Zolgensma?
The price reflects the single-use, curative nature of the therapy. Market pressures and potential biosimilar entry could reduce prices in the future.
-
What factors influence reimbursement decisions for this therapy?
Cost-effectiveness assessments, negotiated rebates, patient access programs, and healthcare budgets significantly impact reimbursement.
-
How might expanded indications impact sales?
Approval for older age groups and broader SMA subtypes would increase the eligible patient pool, boosting revenues.
-
Are there international price differences?
Yes, prices outside the U.S. tend to be 20-50% lower due to different pricing regulations and healthcare systems.
References
[1] SMA Foundation. (2021). Spinal muscular atrophy: Epidemiology and patient prevalence. https://smaf.org
[2] U.S. Food and Drug Administration. (2019). Zolgensma approval letter. https://www.fda.gov
[3] IQVIA. (2022). Global gene therapy market report.
[4] ICER. (2021). Assessment of gene therapies for SMA. https://icer.org
